In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
News|Articles|October 12, 2023
GSK and Zhifei Partner to Extend the Availability of Shingrix
Author(s)Felicity Thomas
The companies will co-promote GSK’s shingles vaccine, Shingrix, to healthcare professionals and points of vaccination in China.
Advertisement
Global biopharma company, GSK, has entered into an exclusive strategic partnership with Chongqing Zhifei Biological Products Co. (Zhifei)—a fully-integrated biotechnology company—to co-promote GSK’s shingles vaccine, Shingrix, to healthcare professionals and points of vaccination in China.
According to an Oct. 9, 2023 press release, the partnership, which has been set to last for an initial three-year period with the option to extend in the future, will broaden the availability of Shingrix in China significantly. Additionally, the partnership is expected to support future co-development and commercialization in China of GSK’s respiratory syncytial virus (RSV) vaccine, Arexvy, for adults aged 60 years and older.
The agreement is set to begin on Jan. 1, 2024 and will see Zhifei gain the exclusive rights for the importation and distribution of Shingrix within China, while GSK will co-promote the vaccine in the country through raising awareness of the importance of shingles vaccination for healthcare professionals. Under the terms of the agreement, Zhifei will buy agreed upon volumes of Shingrix that will equate to a total value of £2.5 billion ($3.1 billion) to GSK over the course of three years. The volumes of the vaccine purchased will be phased over time to accommodate the expected increase in demand as the vaccine and its importance are promoted. Further, as a part of the terms of the partnership, Zhifei has given GSK the right of first refusal to be the exclusive partner for a similar arrangement for GSK’s Arexvy vaccine once it has been approved in China.
“This partnership is consistent with our focus on products with a high and durable level of differentiation,” said Luke Miels, chief commercial officer, GSK, in the press release. “It materially expands the number of Chinese adults who can benefit from Shingrix and includes the option to extend the collaboration to include our novel RSV vaccine Arexvy.”
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
Full phase 3 OASIZ-301 results show both dosing regimens of Amgen’s CD40L antagonist fusion protein dazodalibep reduced systemic disease activity in Sjögren’s disease at Week 48. The every-four-weeks dose also improved patient-reported dryness.
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5